Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Lampros Papadimitriou , Charles K Moore , Javed Butler , et al Added: 4 years ago
Heart failure (HF) is a global epidemic which affects about 6 million adults in the US. It is projected that by 2030 the total cost of HF will reach US$70 billion. Despite the development of novel drugs and devices, the mortality burden of HF remains high, with one in three patients dying within 1 year of hospitalisation for HF and 40–50% within 5 years of diagnosis.1 Patients with HF are… View more
Author(s): Estefania Oliveros , Yevgeniy Brailovsky , Paul Scully , et al Added: 3 years ago
This review focuses on the implications of coronavirus disease 2019 (COVID-19) in the heart failure (HF) population. First of all, we will describe the cardiovascular implications of COVID-19 and the new practices surrounding the use of telehealth to follow up and triage patients with HF. We will then discuss the current practices supported by medical societies, the role of pharmacotherapy and,… View more
Author(s): Syed Yaseen Naqvi , Ibrahim G Salama , Ayhan Yoruk , et al Added: 3 years ago
Heart failure is a progressive and fatal disease that affects more than 23 million people worldwide, and will affect more than 8 million people in the USA by 2030.1,2 Despite major advancements in medical and device treatments for heart failure in recent decades, the incidence of heart failure continues to rise. This epidemic has a major impact on patient quality of life, while imposing heavy… View more
Author(s): Andrew JS Coats , Louise G Shewan Added: 3 years ago
What is Heart Failure? Heart failure (HF) is a diagnosis made on clinical grounds, requiring at its simplest only a clinical history and physical examination findings, although, of course, certain investigations can help, especially imaging to assess left ventricular (LV) mechanical function. Unlike cancer, or even myocardial infarction (MI), there is no pathological or biochemical test that is… View more
Author(s): Marco Bergonti Added: 1 year ago
EHRA 23 - Dr Marco Bergonti (Istituto Cardiocentro Ticino, CH) to discuss the key takeaways from the ANTWOORD II Trial. In this study, 605 heart failure patients undergoing atrial fibrillation ablation were enrolled to receive an ANTWERP Score, which aimed to predict LVEF recovery. 70% of patients were categorised as 'responders', patients identified as those who could benefit the most from AF… View more